Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$26.37
$0.40(1.28%)
At close: 4:00 PM EDT
$26.37
$0.40(1.28%)
Day’s Range― - ―
52-Week Range$16.10 - $33.07
Previous Close$31.59
Volume994.73K
Average Volume (3M)1.10M
Market Cap
$2.02B
Enterprise Value$2.16K
Total Cash (Recent Filing)$152.63M
Total Debt (Recent Filing)$26.97M
Price to Earnings (P/E)27.4
Beta0.59
Next Earnings
Oct 29, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding76,726,800
10 Day Avg. Volume999,641
30 Day Avg. Volume1,100,930
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$34.30Price Target Upside30.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.28
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionProgyny has scaled revenue substantially while improving operating and net margins. This indicates growing employer adoption and operating leverage, although continued execution will be needed to sustain profitability as the business matures.
Strong Cash Generation And Balance SheetHigh operating and free cash flow, combined with minimal debt, gives Progyny substantial financial flexibility. The company can fund platform investment, withstand utilization variability, and return capital without relying heavily on external financing.
Client Growth And RetentionExpansion across employer clients and covered lives supports recurring benefits revenue and strengthens network scale. Strong retention and renewal activity also improve revenue durability by reducing dependence on continual replacement of lost accounts.
Bears Say
Moderating Growth And Moderate Gross MarginsGrowth is moderating from earlier expansion levels, while gross margin remains moderate for a specialized benefits platform. This may limit operating leverage and requires continued care-management efficiency to support durable profit improvement.
Active Competitive EnvironmentCompetition for employer accounts can pressure retention, contract economics, and customer-acquisition efficiency. Progyny’s success in brownfield opportunities is encouraging, but a dynamic market means its care model and provider network must remain differentiated.
Slow Ramp Of New Growth ChannelsNew distribution and product channels may broaden Progyny’s addressable market, but their delayed contribution leaves near-term growth reliant on the established employer channel. Longer ramps increase execution risk and postpone diversification of revenue drivers.
Progyny News
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $16.10 and its highest was $33.06 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $2.02B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Aug 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.005.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.31.
How many shares outstanding does Progyny have?
Progyny has 76,726,800 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.34 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went down -6.984%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.30 (30.07% Upside)
$34.30 (30.07% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 163.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Progyny
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
PGNY Company Deck
PGNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong financial and operational positives: record quarterly results, margin expansion, robust operating cash flow ($201M TTM), a clean balance sheet, sizable share repurchases, and meaningful early sales momentum with confidence to add 1M+ lives. The primary negatives were a slightly more pronounced summer seasonality that tempered near-term visibility and required modest guidance recalibration, comparability noise from a prior transition client, and early-stage nature of new channels (Progyny Select). Overall the positive financial performance, cash generation, and sales/retention momentum materially outweigh the transitory seasonality and execution timing risks described.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$34.30
▲(30.07% Upside)
Technical Analysis
Ownership Overview
2.87% Insiders
33.06% Mutual Funds
21.73% Other Institutional Investors
9.64% Public Companies and
Individual Investors